VIRP Stock Overview
Manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for VIRP from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Virbac SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €313.00 |
| 52 Week High | €400.00 |
| 52 Week Low | €306.00 |
| Beta | 0.97 |
| 1 Month Change | -1.26% |
| 3 Month Change | -21.75% |
| 1 Year Change | -11.58% |
| 3 Year Change | -26.44% |
| 5 Year Change | 29.34% |
| Change since IPO | 2,447.19% |
Recent News & Updates
An Intrinsic Calculation For Virbac SA (EPA:VIRP) Suggests It's 47% Undervalued
Oct 06
Virbac SA Just Beat Revenue Estimates By 6.0%
Sep 18Unpleasant Surprises Could Be In Store For Virbac SA's (EPA:VIRP) Shares
Aug 31Recent updates
An Intrinsic Calculation For Virbac SA (EPA:VIRP) Suggests It's 47% Undervalued
Oct 06Virbac SA Just Beat Revenue Estimates By 6.0%
Sep 18Unpleasant Surprises Could Be In Store For Virbac SA's (EPA:VIRP) Shares
Aug 31Why We Think Virbac SA's (EPA:VIRP) CEO Compensation Is Not Excessive At All
Jun 15Are Investors Undervaluing Virbac SA (EPA:VIRP) By 34%?
Jun 10Virbac SA (EPA:VIRP) Investors Are Less Pessimistic Than Expected
May 21Here's What Analysts Are Forecasting For Virbac SA (EPA:VIRP) After Its Yearly Results
Mar 22Is Virbac SA (EPA:VIRP) Trading At A 23% Discount?
Jan 18Virbac SA's (EPA:VIRP) Shares Climb 25% But Its Business Is Yet to Catch Up
Dec 27Virbac (EPA:VIRP) Has A Pretty Healthy Balance Sheet
Oct 19Is There An Opportunity With Virbac SA's (EPA:VIRP) 40% Undervaluation?
Sep 26Here's Why We Think Virbac (EPA:VIRP) Is Well Worth Watching
Sep 05A Look At The Fair Value Of Virbac SA (EPA:VIRP)
Jun 20Does Virbac (EPA:VIRP) Deserve A Spot On Your Watchlist?
May 31Is Virbac (EPA:VIRP) Using Too Much Debt?
Apr 09Are Investors Undervaluing Virbac SA (EPA:VIRP) By 34%?
Feb 28Virbac SA (EPA:VIRP) Shares Could Be 50% Below Their Intrinsic Value Estimate
Nov 25Does Virbac (EPA:VIRP) Have A Healthy Balance Sheet?
Oct 14An Intrinsic Calculation For Virbac SA (EPA:VIRP) Suggests It's 42% Undervalued
Aug 07These 4 Measures Indicate That Virbac (EPA:VIRP) Is Using Debt Safely
Jun 26Virbac SA (EPA:VIRP) Shares Could Be 38% Below Their Intrinsic Value Estimate
May 01We Think Virbac (EPA:VIRP) Can Manage Its Debt With Ease
Mar 26Virbac SA (EPA:VIRP) Shares Could Be 36% Below Their Intrinsic Value Estimate
Jan 26Here's Why I Think Virbac (EPA:VIRP) Is An Interesting Stock
Dec 28A Look At The Fair Value Of Virbac SA (EPA:VIRP)
Oct 27Is Virbac (EPA:VIRP) Using Too Much Debt?
Oct 12Here's Why I Think Virbac (EPA:VIRP) Might Deserve Your Attention Today
Sep 26Is Virbac SA (EPA:VIRP) Trading At A 22% Discount?
Jul 15Is Now The Time To Put Virbac (EPA:VIRP) On Your Watchlist?
Jun 27Is Virbac (EPA:VIRP) A Risky Investment?
May 27Robust Earnings May Not Tell The Whole Story For Virbac (EPA:VIRP)
Mar 24Are Investors Undervaluing Virbac SA (EPA:VIRP) By 32%?
Mar 12Here's Why We Think Virbac (EPA:VIRP) Is Well Worth Watching
Feb 22Is Virbac SA (EPA:VIRP) Popular Amongst Insiders?
Feb 03
Virbac SA's (EPA:VIRP) Stock Is Going Strong: Is the Market Following Fundamentals?
Jan 05Does Virbac's (EPA:VIRP) Share Price Gain of 96% Match Its Business Performance?
Dec 18Shareholder Returns
| VIRP | FR Pharmaceuticals | FR Market | |
|---|---|---|---|
| 7D | -3.7% | -0.1% | -0.4% |
| 1Y | -11.6% | 2.3% | -4.1% |
Return vs Industry: VIRP underperformed the French Pharmaceuticals industry which returned 2.3% over the past year.
Return vs Market: VIRP underperformed the French Market which returned -4.1% over the past year.
Price Volatility
| VIRP volatility | |
|---|---|
| VIRP Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 3.6% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.6% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: VIRP has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: VIRP's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 5,459 | Habib Ramdani | corporate.virbac.com |
Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners.
Virbac SA Fundamentals Summary
| VIRP fundamental statistics | |
|---|---|
| Market cap | €2.62b |
| Earnings (TTM) | €141.19m |
| Revenue (TTM) | €1.34b |
18.6x
P/E Ratio2.0x
P/S RatioIs VIRP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIRP income statement (TTM) | |
|---|---|
| Revenue | €1.34b |
| Cost of Revenue | €446.54m |
| Gross Profit | €892.83m |
| Other Expenses | €751.63m |
| Earnings | €141.19m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 14, 2025
| Earnings per share (EPS) | 16.86 |
| Gross Margin | 66.66% |
| Net Profit Margin | 10.54% |
| Debt/Equity Ratio | 37.2% |
How did VIRP perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield8%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 01:55 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Virbac SA is covered by 14 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laurent Gelebart | BNP Paribas Exane |
| Carole Rozen | CA Cheuvreux |
| Arnaud Cadart | CIC Market Solutions (ESN) |